

The LSDRC funded seven researchers who applied for the NIH PAS-04-120 but who did not receive NIH funding. The total amount of grants awarded is \$233,000 from the available \$310,000. The decisions for funding from the LSDRC were made by an independent review board of scientists and clinicians who serve on the advisory boards of the participating LSDRC groups. We are very pleased with the success of this collaboration among the LSD support groups and the NIH.

Eain M. Cornford, PhD, Professor of Neurology
David Geffen School of Medicine at UCLA, Veterans Affairs Greater Los Angeles
Healthcare System
“Gene delivery across the blood-brain barrier in Lafora knockout mice”

Philip E. Dawson, PhD, Assoc. Professor, Cell Biology
Scripps Research Institute, LaJolla, CA
“Potential of chemical chaperones and thioester reactive small molecules as potential
therapeutic approaches in the treatment of infantile Batten disease”

Kostantin Dobrenis, PhD, Asst. Professor, Neuroscience, Co-Director, Center for
Disorders of Lysosomal Metabolism
Albert Einstein College of Medicine
"GM2 Gangliosidosis Therapy Using Neuronotropic Enzyme"

Angela Gritti, PhD,
Institute for Stem Cell Research (SCRI), Milan, Italy
“Neural Stem Cell Based Therapy for GM2 Gangliosidosis”

Synthia H. Mellon, PhD, Prof, Ob/Gyn. Reproductive Sciences
Univ. of California at San Francisco
“Neurosteroid Therapy for Lysosomal Storage Disorders”

Thomas N Seyfried, PhD, Prof. of Biology
Boston College
“Evaluate MJ-DGJ as a substrate reduction therapy, neural stem cells (NSCs), as a cross-
correctional therapy, and caloric restriction (CR) as an anti-inflammatory therapy for
ganglioside storage diseases”

Brian W. Soper, PhD, Research Staff Scientist
The Jackson Laboratory
“MPS VII CNS Gene Therapy Using Neuronal Stem Cells”

Dr. Elizabeth Neufeld was the recipient of an NIH grant for her work “Aptamer-directed
crossing of the blood brain barrier for enzyme therapy of LSDs”.